BNT211 With or Without CARVac Shows Early Activity in CLDN6+ R/R Advanced Solid Tumors

The Claudin-6–directed CAR T-cell therapy, BNT211, showed signs of clinical activity in patients with CLDN6-positive relapsed or refractory solid tumors.

Related Keywords

Netherlands ,Roche Genentech ,Merck Serono ,Iovance Bio ,Asher Bio ,Pfizer ,Astrazeneca ,Amgen ,Translational Immunotherapy Of Cancer At Leiden University ,Bristol Myers Squibb ,Novartis ,Leiden University ,Instil Bio ,Molecular Partners ,Neogene Therapeutics ,Third Rock Ventures ,Sastra Cell ,Bnt211 ,Carvac ,Cldn6 ,Solid Tumors ,Cart Cell Therapy ,Bnt211 01 Trial ,Jesmo ,